No, Ketorolac (Toradol) Should NOT Be Given to Patients Presenting with Chest Pain
Ketorolac is explicitly contraindicated in the setting of acute coronary syndromes and should be avoided in patients with undifferentiated chest pain until cardiac causes are definitively ruled out. 1, 2, 3
Why Ketorolac is Contraindicated in Chest Pain
Direct Guideline Contraindications
The FDA drug label for ketorolac explicitly states it is contraindicated in the setting of coronary artery bypass graft (CABG) surgery 3, and multiple cardiovascular guidelines specifically warn against NSAID use in acute coronary syndromes:
- NSAIDs (except aspirin) should NOT be administered during hospitalization for STEMI due to increased risk of mortality, reinfarction, hypertension, heart failure, and myocardial rupture 1
- NSAIDs should not be initiated and should be discontinued during hospitalization for NSTE-ACS because of increased risk of major adverse cardiac events (Class III: Harm recommendation) 2
Cardiovascular Thrombotic Risk
The FDA black box warning for ketorolac explicitly states: "NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment." 3 This is particularly concerning in chest pain patients where acute coronary syndrome is in the differential diagnosis.
Additional Contraindications Relevant to Chest Pain Evaluation
Ketorolac has multiple contraindications that may apply to chest pain patients 3:
- Active peptic ulcer disease or GI bleeding (chest pain can be referred from GI sources)
- Advanced renal impairment (common in cardiac patients)
- Hemorrhagic diathesis or high bleeding risk (problematic if anticoagulation or antiplatelet therapy needed)
- Suspected cerebrovascular bleeding (chest pain with neurologic symptoms)
The Correct Approach to Chest Pain Management
Initial Treatment Algorithm
For patients presenting with chest pain 4, 1, 2:
- Activate EMS/obtain immediate ECG - differentiate STEMI from NSTE-ACS
- Administer aspirin 162-325 mg (chewed, unless contraindicated) 5, 1
- Sublingual nitroglycerin 0.3-0.4 mg every 5 minutes × 3 doses for ongoing ischemic pain 1, 2
- IV nitroglycerin for persistent ischemia, heart failure, or hypertension 2
- Morphine sulfate IV for chest discomfort unresponsive to nitrates (Class I recommendation) 1, 2
- Oral beta-blockers within first 24 hours if no contraindications 1, 2
Appropriate Analgesic Choice
Morphine is the preferred analgesic for cardiac chest pain 1, 2. The 2015 AHA guidelines state: "Providers should administer analgesics, such as intravenous morphine, for chest discomfort unresponsive to nitrates. Morphine is the preferred analgesic for patients with STEMI" (Class I, Level of Evidence C) 1.
For NSTE-ACS, morphine may be reasonable when symptoms are not immediately relieved with nitroglycerin and beta-blocker, or when acute pulmonary congestion or agitation is present 4, 2.
When Ketorolac Might Be Considered
Ketorolac can only be considered after cardiac causes have been definitively excluded through:
- Serial troponins (negative at 0 and 6-12 hours)
- ECG showing no ischemic changes
- Clinical assessment ruling out ACS
Even then, ketorolac should only be used for confirmed musculoskeletal chest pain 6, 7 or other non-cardiac causes where its risks are justified.
Critical Pitfalls to Avoid
- Never assume chest pain is musculoskeletal without cardiac workup - up to 4% of chest pain in older adults is myocardial infarction 5
- Do not use "response to ketorolac" as a diagnostic test - pain relief does not rule out cardiac etiology
- Remember that women, diabetics, and elderly patients may present with atypical symptoms 8
- Ketorolac's 30-60 minute onset 9 makes it inappropriate for acute severe pain requiring rapid relief anyway
The bottom line: In undifferentiated chest pain, reach for morphine and nitroglycerin, not ketorolac. NSAIDs have no role in the acute management of potential cardiac chest pain and carry significant harm.